TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects age 18 year old or older who are eligible candidates for myeloablative autologous stem cell transplantation (ASCT).~* Subjects receiving etoposide as part of their conditioning regimen with a planned total dose of ≥ 30 mg/kg.~Exclusion Criteria:~* Subjects with prior radiation to head \& neck region.~* Subjects with known oropharynx involvement with their malignancy.~* Subjects with a history of non-compliance or who lack capacity to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Cryotherapy Group (Group A) (Type: ACTIVE_COMPARATOR): Subjects in the intervention group will receive both standard oral care and cryotherapy. During the 30 minute cryotherapy periods, subjects will eat ice chips, and/or consume very cold or frozen foods. Cryotherapy will begin 15 minutes prior to the start time of each etoposide infusion. After 30 minutes of cryotherapy, subjects will begin the saline rinses. The subject should perform 3 saline rinses over 15 minutes. After 15 minutes of saline rinses, the 30-minute cryotherapy / 15-minute saline rinse cycles will be repeated until 30 min after completion of etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
- Standard Oral Care Group (Group B) (Type: ACTIVE_COMPARATOR): Subjects in the control group will receive standard oral care only. At the beginning of each etoposide infusion, the subject will begin the saline rinses. The subject will perform 3 saline rinses over 15 minutes followed by 30 minutes of rest (no rinses). The 15-minute saline rinse / 30-minute rest cycles will be repeated until 30 minutes after the completion of the etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Health Promoting Conversations for Families With a Critically Ill Relative

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* patient age \>18 years~* patient treated in the ICU for at least 96 hours~* at least one family member (age \>15 years) interested in participating~Exclusion criteria:~* dementia~* or other severe psychiatric illnesses~* drug abuse~* difficulties in understanding or reading the Swedish language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- The health-promoting conversations (Type: EXPERIMENTAL): In the intervention group, there were 3 health-promoting conversations with each family after the discharge. The health-promoting conversations were held within an approximately 4- to 8-week period with an interval of 2 weeks between conversations. A closing letter was sent 2 to 3 weeks after the final conversation that summarized all of the conversations and that provided further opportunities for reflection.
- Control Arm (Type: ACTIVE_COMPARATOR): Usual Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Blood Flow Evaluation With Trancranial Doppler After Interscalene Nerve Block

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing orthopedic surgery and with an indication for preoperative insertion of interscalene nerve block~* 18-85 years old~* Give consent to participate in study~Exclusion Criteria:~* Cannot give consent~* Patients who are clinically unstable or require urgent/emergent intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Arm (Type: None): Patients ages 18-85 years old presenting with orthopedic shoulder surgery with indication to receive preoperative insertion of interscalene nerve block.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants are actively enrolled in an Anthem-affiliated commercial, Medicaid, or Medicare health plan with medical and pharmacy benefits.~* Participants must have a smartphone with data plan.~* Participants currently prescribed aripiprazole, or appropriate for aripiprazole treatment.~* Participants must have a current diagnosis of SCH, BP1, or MDD.~Exclusion Criteria:~* Any participant who participated in another clinical trial within 30 days of enrollment into the current study.~* Females who are breast-feeding and/or who are pregnant at the time of study enrollment, or who plan to become pregnant during the study.~* Participants who are currently being treated with a long-acting injectable antipsychotic.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 63 Years
- Healthy Volunteers: f

Study Arms:
- Abilify MyCite (Type: EXPERIMENTAL): Participants received Abilify MyCite during Months 1-3. During Months 4-6 use of Abilify MyCite was to be prohibited. Thereafter, at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) could have been initiated per the joint decision of the participants with their study physician.
- Virtual Matched Controls (Type: ACTIVE_COMPARATOR): Virtual matched controls were to receive treatment as usual (that is, any product other than Abilify MyCite, which could have been oral aripiprazole or any other product) throughout the duration of the trial. Virtual matched controls were not to be enrolled into the study, but identified from health insurance claims data and matched to the enrolled Abilify MyCite participants at the end of the study for analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children and adults with hemophilia A or B, ages 1-21 who have CVLs for factor infusion and who are prescribed factor prophylaxis for treatment of their bleeding disorder will be included.~* Subjects will be recruited from active patients at federally funded hemophilia treatment centers (HTCs).~Exclusion Criteria:~* None

- Gender: MALE
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Hemophilia Patients (Type: None): Subjects diagnosed with moderate or severe Hemophilia A or B who use a central venous line (CVL) for regular prophylaxis factor infusions and are at the clinic for a standard of care visit. As part of the study all subjects will have blood drawn through their CVL and will also undergo a peripheral vein blood draw.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed of primary or mixed dementia (CIE 10criteria)~* Weihgt loss \>5% of habitual weight in the last 6 months and proteic-caloric malnutrition (MNA \<17)~* Outpatients~* Patients that accept the participation in the study~Exclusion Criteria:~* Vascular pure Dementia and secondary dementias( vascular dementia, Parkinson disease,etc)~* Dementia in a terminal phase: category of FAST 7c in the Reisber scale~* Concomitant treatment with steroids, androgens or other drugs with progestagens~* Weight loss secondary to neoplasia

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Megestrol acetate 160 mg b.i.d. during 24 weeks
- 2 (Type: PLACEBO_COMPARATOR): 1 sachet of powder of placebo b.i.d. during 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Determinants of the Vascular Response to Training in Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~A/ COPD patients~* age between 35 and 85 years old~* spirometry showing an FEV1/VC \< lower limit of normal~* with an indication for a pulmonary rehabilitation program~* written and informed consent for this study signed by the patient~B/ Healthy subjects~* age between 35 and 85 years old~* no cardiovascular or respiratory disease~* normal spirometry~Exclusion Criteria:~* Unstabilized comorbidity~* Subject in a period of exclusion relative to another protocol~* Major protected by law~* Subject participating in another research protocol~* Subject not affiliated to a social security scheme~* Pregnant or lactating woman~* Patient deprived of freedom by court or administrative order

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- COPD patients (Type: EXPERIMENTAL): FMD analysis Endothelial progenitors Exercise test Exercise training
- Healthy subject (Type: EXPERIMENTAL): FMD analysis Endothelial progenitors Exercise test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Electromyographic Biofeedback on Quadriceps Neuromuscular Function in Patients With Quadriceps Inhibition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of primary and uncomplicated knee injury or knee surgery.~* Aged 18-40~* Quadriceps Central Activation Ratio is less than 90%~Exclusion Criteria:~* Currently seeking physical therapy~* Complex knee injury~* Surgical revisions to original procedure~* Pain greater than 4 out of 10 on a visual analog scale at enrollment.~* Active infection~* Current pregnancy~* Cognitive impairment~* Psychiatric disorder requiring daily medication~* Chronic or acute neuropathy~* Known muscular abnormalities~* History of neurological disorders~* History or family history of seizures and/or epilepsy and/or on medications that lower seizure threshold

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Electromyographic Biofeedback Group (Type: EXPERIMENTAL): Participants in the electromyographic biofeedback supplemented exercise will be instructed on correct setup and use of the electromyographic biofeedback unit. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group. Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
- Traditional Exercise Group (Type: ACTIVE_COMPARATOR): Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exergaming to Increase Physical Activity in Overweight/Obese Children and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Defined as overweight/obese for age and sex~* Able to ride a bike for up to 60 minutes~Exclusion Criteria:~* Known cardiovascular disease~* Taking beta-blockers or anti-arrhythmic drugs~* Other diseases that restrict them from doing High-Intensity Training

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- Exergaming (Type: EXPERIMENTAL): The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
- Control (Type: NO_INTERVENTION): Continue with normal daily routine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Edi Level and Cardiopulmonary Function Between HHHFNC and Unheated Humidified High-Flow Oxygen Mask in COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. AE of COPD received intubation and ready to be weaning~2. P/F ratio \> 200 during SBT before extubation~Exclusion Criteria:~1. Unable to insert NG tube~2. Refuse to re-intubated when respiratory failure after extubation~3. Planned NIV use after extubation~4. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HHHFNC group (Type: EXPERIMENTAL): On HHHFNC FiO2 will setting as same as SBT before extubation Flow rate: 50L/min
- UHFOM group (Type: SHAM_COMPARATOR): On Aerosol mask FiO2 will setting as same as SBT before extubation Flow rate: 15L/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Prostate Tumor Localization for Focal Cryoablation of Prostate Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who have been diagnosed with prostate cancer and are scheduled for radical prostatectomy or for brachytherapy~* patients who have not received any preoperative treatment for their diagnosis of prostate cancer~Exclusion Criteria:~* patients with implants that are electronically, magnetically, or mechanically active~* patients with intracranial aneurysm clips~* patients who have undergone cosmetic eyelid surgery~* patients with history of pheochromocytoma, insulinoma and acute glaucoma~* patients with estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73m2

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Radical prostatectomy patients (Type: OTHER): Patients who have been diagnosed with prostate cancer and are scheduled to undergo radical prostatectomy and have not received any preoperative treatment for prostate cancer.
- Brachytherapy patients (Type: OTHER): Patients who have been diagnosed with prostate cancer and are scheduled to undergo brachytherapy and have not received any preoperative treatment for prostate cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intermittent Oro-esophageal Tube Feeding on Severe Traumatic Brain Injury Patients With Tracheostomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years, meeting the diagnosis of severe Traumatic Brain Injury, confirmed through MRI~* score of Glasgow Coma Scale (GCS) \<8;~* presence of no contraindication for enteral nutrition;~* with stable vital signs and no severe liver or kidney dysfunction, metabolic disorders, cardiovascular diseases, or multiple complications;~* informed consent form was obtained from the patient\&#39;s family members, indicating their full understanding of the study and agreement to participate.~Exclusion Criteria:~* unable to cooperate in completing treatment and assessment due to personal reasons or other disorders;~* complicated with other intracranial lesions, such as stroke;~* with severe consciousness disorders caused by other diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- the observation group (Type: EXPERIMENTAL): Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy.Based on this, the patients in the observation group were given enteral nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University).
- the control group (Type: ACTIVE_COMPARATOR): Both groups of patients were provided with routine treatments, including pharmacological treatment, rehabilitation therapy. The patients in the control group were provided nutrition support with Nasogastric tube feeding , while the feeding process strictly followed the relevant guideline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will include patients undergoing radical prostatectomy for prostate cancer. Subjects will be randomized into control or treatment group.~Exclusion Criteria:~* Subjects with a history of adverse reaction to ciprofloxacin, or any other quinolone will be excluded. Subjects being treated with tizanidine or with a history of myasthenia gravis will be excluded. In addition, we will exclude patients with major immediate post-operative complications after prostatectomy including significant post-operative bleeding with known pelvic hematoma and known urine leak.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ciprofloxacin (Type: ACTIVE_COMPARATOR): Antibiotic
- No Antibiotic (Type: NO_INTERVENTION): No Antibiotic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Post-menopausal woman with Urogenital ageing (UGA)~* Recurrent urinary tract infections defined as three or more urinary tract infections within the past twelve months~Exclusion Criteria:~* Known or suspected allergy to trial product or related products~* Present UTI~* History of RUTI during fertile period of life

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues